Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Vanguard Real Estate Index Fund ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Vanguard Real Estate Index Fund ETF trades at $90.36 (market cap $70.80B). The key difference: Vanguard Real Estate Index Fund ETF is far larger — about 9.4× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Vanguard Real Estate Index Fund ETF for 113 Days on average.
| SYRE | VNQ | |
|---|---|---|
Market Cap | $7.52B | $70.80B |
Volume | 1,441,031 | 3,568,223 |
Sector | Health | — |
52-Week High | $108.92 | $100.95 |
52-Week Low | $22.18 | $87.00 |
Typical Hold Time | 0 Days | 113 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
VNQ, the Vanguard Real Estate ETF, trades at $91.14, down 0.24% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. Recent news highlights pressure from rising Treasury yields and Fed rate hikes, contributing to a nearly 10% decline over the past month. The ETF's dividend yield is now competitive with T-bills, but sector headwinds persist due to interest rate sensitivity.
Outlook remains cautious amid interest rate uncertainty, with potential long-term value for contrarian investors. Risks include further rate hikes eroding income appeal, while opportunities lie in historically attractive entry points for well-capitalized REITs. Investors should weigh yield sustainability against macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
